Have a feature idea you'd love to see implemented?
Let us know!

- Stocks
- Healthcare
- NASDAQ: IONS

Price (delayed)

$37.81

Market cap

$5.53B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.52

Enterprise value

$6.68B

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and

IONS's revenue is up by 29% YoY and by 4.7% QoQ

The gross profit is up by 29% year-on-year and by 4.6% since the previous quarter

The net income has declined by 18% year-on-year but it has increased by 4.9% since the previous quarter

Ionis Pharmaceuticals's EPS has decreased by 16% YoY but it has increased by 6% QoQ

The company's equity fell by 38% YoY and by 11% QoQ

IONS's quick ratio is down by 18% year-on-year

What are the main financial stats of IONS

Market
Valuations
Earnings

Shares outstanding

146.21M

Market cap

$5.53B

Enterprise value

$6.68B

Price to book (P/B)

20.93

Price to sales (P/S)

6.78

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

8.21

Revenue

$813.46M

EBIT

-$263.22M

EBITDA

-$240.79M

Free cash flow

-$358M

Per share
Balance sheet
Liquidity

EPS

-$2.52

Free cash flow per share

-$2.45

Book value per share

$1.81

Revenue per share

$5.57

TBVPS

$18.44

Total assets

$2.69B

Total liabilities

$2.43B

Debt

$1.44B

Equity

$263.7M

Working capital

$2.02B

Debt to equity

5.47

Current ratio

7.61

Quick ratio

6.88

Net debt/EBITDA

-4.77

Margins
Efficiency
Dividend

EBITDA margin

-29.6%

Gross margin

98.6%

Net margin

-45%

Operating margin

-44.9%

Return on assets

-12.9%

Return on equity

-115.9%

Return on invested capital

-7.4%

Return on capital employed

-11%

Return on sales

-32.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Ionis Pharmaceuticals stock price performed over time

Intraday

-3.99%

1 week

-8%

1 month

-20.08%

1 year

-12.86%

YTD

-25.26%

QTD

-5.62%

How have Ionis Pharmaceuticals's revenue and profit performed over time

Revenue

$813.46M

Gross profit

$801.89M

Operating income

-$364.99M

Net income

-$365.74M

Gross margin

98.6%

Net margin

-45%

The operating margin is up by 40% year-on-year and by 10% since the previous quarter

IONS's revenue is up by 29% YoY and by 4.7% QoQ

The gross profit is up by 29% year-on-year and by 4.6% since the previous quarter

IONS's operating income is up by 23% year-on-year and by 6% since the previous quarter

What is Ionis Pharmaceuticals's growth rate over time

What is Ionis Pharmaceuticals stock price valuation

P/E

N/A

P/B

20.93

P/S

6.78

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

8.21

Ionis Pharmaceuticals's EPS has decreased by 16% YoY but it has increased by 6% QoQ

The stock's price to book (P/B) is 87% more than its 5-year quarterly average of 11.2 but 4% less than its last 4 quarters average of 21.8

The company's equity fell by 38% YoY and by 11% QoQ

IONS's revenue is up by 29% YoY and by 4.7% QoQ

The P/S is 25% less than the last 4 quarters average of 9.1 and 16% less than the 5-year quarterly average of 8.1

How efficient is Ionis Pharmaceuticals business performance

IONS's return on equity has dropped by 95% year-on-year and by 7% since the previous quarter

Ionis Pharmaceuticals's return on sales has increased by 15% YoY and by 9% QoQ

IONS's return on assets is down by 13% year-on-year but it is up by 2.3% since the previous quarter

Ionis Pharmaceuticals's ROIC has decreased by 6% YoY but it has increased by 3.9% from the previous quarter

What is IONS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for IONS.

How did Ionis Pharmaceuticals financials performed over time

The total assets is 11% greater than the total liabilities

IONS's quick ratio is down by 18% year-on-year

The current ratio has declined by 16% year-on-year but it rose by 3.3% since the previous quarter

Ionis Pharmaceuticals's debt to equity has soared by 57% YoY and by 12% from the previous quarter

The company's equity fell by 38% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.